Private Sector Prescribing Practices for TB Symptoms in KwaZulu-Natal, South Africa:

a cross-sectional, standardized patient study

A Salomon¹, J Boffa^{1,2}, S Moyo³, J Chikovore⁴, T Mkhombo³, G Sulis¹, A Kwan⁵, B Daniels⁶, M Pai^{1,7}, A Daftary ^{1,8,9}

¹ McGill International Tuberculosis Centre, Canada; ²University of KwaZulu-Natal Centre for Rural Health, South Africa; ³Human Sciences Research Council (HSRC), Cape Town, South Africa; ⁴HSRC, Durban, South Africa; ⁵University of California, Berkeley, USA; ⁶The World Bank, USA; ⁷Manipal McGill Centre for Infectious Diseases, India; ⁸Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa; York Univesity, Toronto, Canada



Background

South Africa has a **TB** incidence of **567** per **100,000**¹. In 2015, only **65%** of **454,000** estimated new cases of **TB** were notified to the national **TB** program².

Up to 30% of South Africans seek initial care outside the public system³; these patients may experience greater TB diagnostic delay⁴⁻⁵.

Little is known about quality of TB care in the formal private sector, specifically regarding prescribing practices and ideal case management.

Objectives

PRIMARY: Describe the prescribing practices of private General Practitioners (GPs) treating standardized patients (SPs) who present with tuberculosis symptoms

SECONDARY: Assess ideal case management:

- 1) helpful management (referral or test order)
- 2) no harmful management (inappropriate medicine)

Methodology

Design: Eight cash-paying SPs (6 F, 2 M) presented 1 of 3 TB cases during **unannounced visits** to **consenting GPs**

Study Site: 6 high TB-burden communities within an urban site in Kwa-Zulu Natal, South Africa

Sample Size:

- > 100 GPs (86 male, 14 female), sampled conveniently
- \triangleright **220** interactions (case 1 = 95, case 2 = 50, case 3 = 75)

Data Collection:

- Exit survey:
 History Qs, exams, tests, referrals, patient satisfaction
- Artifact survey: medicines, referral forms

5%

9%

■ No


medicines

Prescribed

| M1 | How many medications were prescribed/dispensed? (If none, write 0 and skip to SECTION 3: TESTS) | | 4 | |
|-----|---|---|--|---------------------------|
| Med | M2: Dispensed (D) or Prescribed (P)? | Name(s) of medicines (M3= brand and M4=generic) If medicines are unlabeled: - In BRAND, write "unlabeled" In GENERIC, describe the colour and shape | M5: Price (if prescribed, use Dis-Chem price. 999 if unknown) | M6: Expired? Y/N/UK |
| 1 | \mathcal{Q} | Generic: Chlorphenamine (4mg) | 999 | UK |
| 2 | D | Generic: Paracetamol (320mg); Meprobamate (150mg); Codeine Phosphate (8 mg) Brand: | 999 | UK |
| 3 | D | Generic: Diphenhydramine HUL (14mg); Amnionium Chloride (13brig); | 999 | 10/201 |
| 4 | 0 | Generic: Deep green capsule (antibiotic) | 999 | ЦK |

TB Case Descriptions

CASE 1: Suspected TB, HIV+



Cough + fever >2 weeks, sputum, loss of weight/ appetite, night sweats, not on ARTs

CASE 2: Confirmed TB, HIV-



Above symptoms + positive GeneXpert report

CASE 3: Suspected MDR-TB, HIV+



Above symptoms +
previous TB diagnosis
and incomplete
treatment, not on ARTs

IDEAL CASE MANAGEMENT:

Helpful: Referral for a TB test OR referral to public clinic/ hospital

AND NOT

Harmful:

Prescription of antibiotics (except co-trimoxazole) or steroids




Results

Dispensed 86% Ideal and Helpful Management, by Case 100% 90% 80% 80% 70% 63% 60% 53% 50% 40% 33% 30% 20% 15% 11% 10% 0% Case 2 Case 3 Overall Case 1 (n=95)(n=50)(n=220)(n=75)

HELPFUL

Management



Key Findings

- ➤ 95% of interactions received 1+ medications; ABX were most commonly prescribed (90%).
 - FQs were prescribed in 12% of interactions (higher than SA public sector)
- Helpful and ideal management occurred in 53% and 11% of interactions, respectively.
- "Confirmed" TB (case 2) had lower rates of antibiotic prescription and higher rates of ideal management

When diagnosis was unclear, GPs resorted to empirical therapies (abx/steroids)

Current prescribing practices may have implications on TB diagnostic delay, immunosuppression in PLHIV, and antimicrobial resistance for patients with TB symptoms in South Africa

References: ¹ WHO Global Tuberculosis Report (2018); ²Naidoo P et al, (2017); ³Chin & Hanson (2017); ⁴Skordis-Worrall J (2010); ⁵Van Wyk SS (2011)

IDEAL

Management

- Acknowledgements: Standardized Patients and participating GPs; research staff at HSRC/McGill University Health Center (N Meyiwa, M Ndlela, L Ntolosi, S Wu, C Vadnais), KZN Doctors Healthcare Coalition; South African Medical Association.
- This study was funded by the Bill and Melinda Gates Foundation